Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06091254
Title A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)
Acronym OLYMPIA-1
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Age Groups: senior | adult
Covered Countries USA | ITA | GBR | ESP | AUT | AUS

No variant requirements are available.